Preliminary trial findings suggest transdermal cannabis may help ease pruritus-related itching in patients undergoing hemodialysis. Cannabis cream relieved itching symptoms over the short-term in a ...

September is the perfect time to turn up the volume on conversations about Primary Biliary Cholangitis (PBC) and the symptoms ...

Dermatologists recently have developed and validated several tools for assessing itch in plaque psoriasis, such as the Peak ...

Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare ...

Japan Pruritus Therapeutics Market was valued at US$ 582.2 million in 2023 and is estimated to surpass the market size of US$ 1,011.5 million by 2032 at a CAGR of 6.33% during the forecast period 2024 ...

South Korea Pruritus Therapeutics Market was valued at US$ 288.01 million in 2023 and is estimated to surpass the market size of US$ 428.01 million by 2032 at a CAGR of 4.50% during the forecast ...

Ipsen’s Kayfanda (odevixibat) has been approved by the European Commission (EC) under exceptional circumstances to treat ...

In the three aforementioned studies of epidural delivery of naloxone in combination with an opioid (fentanyl or morphine), the frequency of pruritus was decreased, with no reversal of analgesia noted.

Mirum Pharmaceuticals, Inc. stock surged 150% on rare disease treatments, but faces challenges with profitability and ...

Kayfanda ® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for Kayfanda ...

Zenrelia is a once-daily oral JAK inhibitor for managing pruritus associated with canine allergic and atopic dermatitis.

Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for ...